137 related articles for article (PubMed ID: 30862120)
41. Reversible Cabozantinib-Induced Cardiomyopathy.
Alhussein M; Hotte SJ; Leong DP
Can J Cardiol; 2019 Apr; 35(4):544.e1-544.e2. PubMed ID: 30935646
[TBL] [Abstract][Full Text] [Related]
42. Phase II Trial of Cabozantinib Plus Erlotinib in Patients With Advanced Epidermal Growth Factor Receptor (
Reckamp KL; Frankel PH; Ruel N; Mack PC; Gitlitz BJ; Li T; Koczywas M; Gadgeel SM; Cristea MC; Belani CP; Newman EM; Gandara DR; Lara PN
Front Oncol; 2019; 9():132. PubMed ID: 30915273
[No Abstract] [Full Text] [Related]
43. Glucocorticoids enhance the antileukemic activity of FLT3 inhibitors in FLT3-mutant acute myeloid leukemia.
Gebru MT; Atkinson JM; Young MM; Zhang L; Tang Z; Liu Z; Lu P; Dower CM; Chen L; Annageldiyev C; Sharma A; Imamura Kawasawa Y; Zhao Z; Miller BA; Claxton DF; Wang HG
Blood; 2020 Aug; 136(9):1067-1079. PubMed ID: 32396937
[TBL] [Abstract][Full Text] [Related]
44. FLT3-ITD Activates RSK1 to Enhance Proliferation and Survival of AML Cells by Activating mTORC1 and eIF4B Cooperatively with PIM or PI3K and by Inhibiting Bad and BIM.
Watanabe D; Nogami A; Okada K; Akiyama H; Umezawa Y; Miura O
Cancers (Basel); 2019 Nov; 11(12):. PubMed ID: 31756944
[TBL] [Abstract][Full Text] [Related]
45. Wu-5, a novel USP10 inhibitor, enhances crenolanib-induced FLT3-ITD-positive AML cell death via inhibiting FLT3 and AMPK pathways.
Yu M; Fang ZX; Wang WW; Zhang Y; Bu ZL; Liu M; Xiao XH; Zhang ZL; Zhang XM; Cao Y; Wang YY; Lei H; Xu HZ; Wu YZ; Liu W; Wu YL
Acta Pharmacol Sin; 2021 Apr; 42(4):604-612. PubMed ID: 32694757
[TBL] [Abstract][Full Text] [Related]
46. Acceleration of slow autophagy flux induced by arabinofuranosyl cytidine improves its antileukemic effectiveness in M-NFS-60 cells.
Fouad SA; El-Sokkary GH; Abdel Shakor AB
Turk J Biol; 2022; 46(4):307-317. PubMed ID: 37529093
[TBL] [Abstract][Full Text] [Related]
47. How ITD Insertion Sites Orchestrate the Biology and Disease of FLT3-ITD-Mutated Acute Myeloid Leukemia.
Haage TR; Schraven B; Mougiakakos D; Fischer T
Cancers (Basel); 2023 May; 15(11):. PubMed ID: 37296951
[TBL] [Abstract][Full Text] [Related]
48. A retrospective assessment of real-world experience with venetoclax and azacitidine therapy in elderly acute myeloid leukemia.
Hu RH; Su L; Lan XX; Chang XL; Hui WH; Guo YX; Zhao H; Zhang Y; Sun WL
Anticancer Drugs; 2023 Mar; 34(3):344-350. PubMed ID: 36622759
[TBL] [Abstract][Full Text] [Related]
49. Genetically regulated expression underlies cellular sensitivity to chemotherapy in diverse populations.
Mulford AJ; Wing C; Dolan ME; Wheeler HE
Hum Mol Genet; 2021 Apr; 30(3-4):305-317. PubMed ID: 33575800
[TBL] [Abstract][Full Text] [Related]
50. A Novel Inhibitor of STAT5 Signaling Overcomes Chemotherapy Resistance in Myeloid Leukemia Cells.
Brachet-Botineau M; Deynoux M; Vallet N; Polomski M; Juen L; Hérault O; Mazurier F; Viaud-Massuard MC; Prié G; Gouilleux F
Cancers (Basel); 2019 Dec; 11(12):. PubMed ID: 31861239
[TBL] [Abstract][Full Text] [Related]
51. Targeting Approaches of Nanomedicines in Acute Myeloid Leukemia.
Huang X; Lin H; Huang F; Xie Y; Wong KH; Chen X; Wu D; Lu A; Yang Z
Dose Response; 2019; 17(4):1559325819887048. PubMed ID: 31853234
[TBL] [Abstract][Full Text] [Related]
52. Metabolic alterations and drug sensitivity of tyrosine kinase inhibitor resistant leukemia cells with a FLT3/ITD mutation.
Huang A; Ju HQ; Liu K; Zhan G; Liu D; Wen S; Garcia-Manero G; Huang P; Hu Y
Cancer Lett; 2016 Jul; 377(2):149-57. PubMed ID: 27132990
[TBL] [Abstract][Full Text] [Related]
53. Targeting Oncogenic Signaling in Mutant FLT3 Acute Myeloid Leukemia: The Path to Least Resistance.
Staudt D; Murray HC; McLachlan T; Alvaro F; Enjeti AK; Verrills NM; Dun MD
Int J Mol Sci; 2018 Oct; 19(10):. PubMed ID: 30332834
[TBL] [Abstract][Full Text] [Related]
54. Genomic instability is a principle pathologic feature of FLT3 ITD kinase activity in acute myeloid leukemia leading to clonal evolution and disease progression.
Rebechi MT; Pratz KW
Leuk Lymphoma; 2017 Sep; 58(9):1-11. PubMed ID: 28278729
[TBL] [Abstract][Full Text] [Related]
55. Cytarabine-Resistant
Ko YC; Hu CY; Liu ZH; Tien HF; Ou DL; Chien HF; Lin LI
Int J Mol Sci; 2019 Mar; 20(5):. PubMed ID: 30862120
[TBL] [Abstract][Full Text] [Related]
56. Cabozantinib is selectively cytotoxic in acute myeloid leukemia cells with FLT3-internal tandem duplication (FLT3-ITD).
Lu JW; Wang AN; Liao HA; Chen CY; Hou HA; Hu CY; Tien HF; Ou DL; Lin LI
Cancer Lett; 2016 Jul; 376(2):218-25. PubMed ID: 27060207
[TBL] [Abstract][Full Text] [Related]
57. Reversal of acquired drug resistance in FLT3-mutated acute myeloid leukemia cells via distinct drug combination strategies.
Zhang W; Gao C; Konopleva M; Chen Y; Jacamo RO; Borthakur G; Cortes JE; Ravandi F; Ramachandran A; Andreeff M
Clin Cancer Res; 2014 May; 20(9):2363-74. PubMed ID: 24619500
[TBL] [Abstract][Full Text] [Related]
58.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
59.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
60.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
